companies

Implicity

Founded 2016
Employees 60+
Primary contact
29, rue du Louvre
75002 Paris
France
+33 (0) 9 61 67 41 14
Links
https://www.implicity.com/
Sections
Technologies
Implicity developed a remote monitoring platform for patients with connected pacemakers and defibrillators across all major manufacturers. Designed for cardiologists and healthcare professionals, it automates remote monitoring of their patients. An artificial intelligence module determines the criticality of each alert considering the medical context of the patient. Implicity has been the first private company authorized to access the Health Data Hub, one of the world's largest patient databases, supporting the development of its AI solutions to improve care for patients with chronic heart failure conditions.
Select partners: MicroPort CRM USA, ClearDATA, Bayer, Withings, HCSG, AI for Health, Plug and Play Cleveland Health Accelerator, EIT Health.
Select clients: Centre Hospitalier Saint Joseph Saint Luc à Lyon, Hôpitaux universitaires Paris Sud, ELSAN Clinique Ambroise Paré - Toulouse, CHU Dijon Bourgogne, Hôpital Paris Saint Joseph, La Clinique Pasteur Toulouse, Hospital Center University De Rouen, Centre Hospitalier d'Avignon, University Hospital Grenoble-Alpes, Groupement des Hôpitaux de l'Institut Catholique de Lille, IronRod Health, Ramsay Santé Hôpital privé de la Loire, Institut Mutualiste Montsouris, Rythmopôle.
Founded 2016
Employees 60+
Primary contact
29, rue du Louvre
75002 Paris
France
+33 (0) 9 61 67 41 14
Links
https://www.implicity.com/
Sections
Technologies

Funding 💰

Total $27.5M
Last round 🔗 $23M
Series A
April 27, 2022.
Select investors Crédit Mutuel Innovation, Bpifrance, Serena, Karista, XAnge, Angelsquare, BNP Paribas Développement

Key people 🧑‍🤝‍🧑

Highlights ⭐

  • Solving a real problem: Current remote monitoring practice is flawed, with multiple vendors requiring multiple systems, making it harder for physicians to do their work. In contrast, Implicity Remote Monitoring platform was designed by an electrophysiologist to answer specific pain points in RM management, delivering better patient care, improved productivity, and optimized workflow.
  • Big market: Millions of patients with Cardiovascular Implantable Electronic Device (CIED) across North America and Europe, let alone the rest of the world, has yet to benefit from remote monitoring -- representing a big opportunity for Implicity.
  • Three solutions: Vendor-neutral Cardiac Remote Monitoring, Advanced Research Tool for collecting real-time data from all cardiac implantable electronic devices, and Heart Failure Module with automatic alerts. 🔗
  • Proven clinical benefits: 66% reduction in hospitalizations for atrial arrhythmia and related stroke, 79% reduction in detection time of clinical events, 58% reduction in-hospital device follow-up visits, 53% reduction the overall mean annual cost per patient, and 34% reduction in all-cause mortality over 3 years for ICD/CRT-D patients. 🔗
  • FDA-cleared: Implicity received FDA clearance for a novel AI algorithm that analyzes ECG episodes from Implantable Loop Recorders (ILRs). 🔗

Video ▶️

Awards & Recognitions 🏆

  • 2022 Hôtel Dieu Project
  • 2020 EIT Health: Prize Winner Bridgehead Europe
  • 2017 Winner of the iLab competition from BPI France (3rd of 1000 startup)
  • 2016 Innovation Price from the "Société Française de Télémédecine" (SFT, Medicen, SNITEM)
  • 2016 Winner of the seal excellence H2020÷//

Quotes 💬

“
We are very pleased to support the commercial expansion of IMPLICITY's cutting-edge platform that enables cardiologists to provide more effective patient care by streamlining data across major remote cardiac monitoring devices. The company is already on a strong growth path in the U.S. and Europe, and we look forward to building on that momentum as they continue to develop next-generation offerings that move toward the prevention of heart disease.
— Delphine Cardi, Investment Director at Crédit Mutuel Innovation 🔗
“
We are extremely impressed by IMPLICITY's current international market success. We believe the company has the potential to become a world-class leader in cardiac remote monitoring. This investment will help accelerate adoption across all regions in 2022 and beyond, particularly in the U.S. This is a very large market opportunity that cannot be overstated.
— Chahra Louafi, Director of the Autonomous Patient Fund at Bpifrance 🔗
“
I am excited by the potential this technology has to transform the practice of remote patient monitoring. The true promise of remote monitoring is that we can see patients who need to be seen earlier. Even if the patient is not experiencing a symptom, we can detect their condition and let them know they need to be seen. Implicity's innovative solutions will enable us to direct our attention to clinically actionable data better so we can do just that.
— Prof. Niraj Varma, MD, Ph.D., a Professor of Medicine and Consultant Electrophysiologist at the Cleveland Clinic 🔗
“
Implicity platform represents the medicine of tomorrow. The challenge today is to sort out the mass of information that doctors receive and effectively manage this influx of data. It necessarily involves AI and IT. We are witnessing a revolution and a digital transformation towards a predictive and personalized medicine.
— Dr. Nicolas Mignot, Institut Mutualiste Montsouris in Paris
Last update: January 13, 2023